Intraocular use of methotrexate (MTX) for the treatment of proliferative vitreoretinopathy (PVR) in congenital aniridia (CI) and a possible link to aniridia fibrosis syndrome (AFS) treatment
Purpose: To present a case of aggressive proliferative vitreoretinopathy (PVR) managed with intraoperative and postoperative intravitreal methotrexate (MTX) in a patient with congenital aniridia (CI). Observations: A 41-year-old female with a history of CI, living-related conjunctival-kerato-limbal...
Saved in:
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2024-12-01
|
| Series: | American Journal of Ophthalmology Case Reports |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S2451993624002263 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850113960638939136 |
|---|---|
| author | Naveen R. Ambati Christopher D. Riemann |
| author_facet | Naveen R. Ambati Christopher D. Riemann |
| author_sort | Naveen R. Ambati |
| collection | DOAJ |
| description | Purpose: To present a case of aggressive proliferative vitreoretinopathy (PVR) managed with intraoperative and postoperative intravitreal methotrexate (MTX) in a patient with congenital aniridia (CI). Observations: A 41-year-old female with a history of CI, living-related conjunctival-kerato-limbal allograft transplantation, and multiple intraocular surgeries presents with tractional retinal detachment (TRD) and aggressive grade C PVR 52 days after a primary 23-gauge pars plana vitrectomy (PPV) with rhegmatogenous retinal detachment repair. She underwent 23-gauge PPV, TRD repair including membrane peeling of pre- and sub-retinal PVR, 5000 centistoke silicone oil exchange, endolaser, and MTX infusion. She received intravitreal 200 μg/0.05mL MTX every two weeks for a total of five injections before switching to monthly injections which have continued indefinitely. Five months after TRD repair, she had a small area of recurrent PVR inferiorly without associated retinal traction. She developed a small epithelial defect that resolved without complication. At 13 months, the patient remains at her visual acuity baseline of 20/125 and an attached retina without progression of PVR. Conclusions and importance: We report a favorable outcome in the management of aggressive PVR with intraoperative and postoperative intravitreal MTX in a patient with CI. Despite a history of limbal stem cell deficiency and receiving numerous MTX injections, keratopathy was minimal. Further research is required to study the safety and efficacy of MTX in the prophylaxis and treatment of aggressive fibrotic responses often seen in CI. |
| format | Article |
| id | doaj-art-6f75686e53f84a3bae01e7e5d58b714e |
| institution | OA Journals |
| issn | 2451-9936 |
| language | English |
| publishDate | 2024-12-01 |
| publisher | Elsevier |
| record_format | Article |
| series | American Journal of Ophthalmology Case Reports |
| spelling | doaj-art-6f75686e53f84a3bae01e7e5d58b714e2025-08-20T02:37:02ZengElsevierAmerican Journal of Ophthalmology Case Reports2451-99362024-12-013610221610.1016/j.ajoc.2024.102216Intraocular use of methotrexate (MTX) for the treatment of proliferative vitreoretinopathy (PVR) in congenital aniridia (CI) and a possible link to aniridia fibrosis syndrome (AFS) treatmentNaveen R. Ambati0Christopher D. Riemann1Department of Ophthalmology at University of Cincinnati, 231 Albert Sabin Way, 5th Floor, Cincinnati, OH, 45267-0527, USA; Cincinnati Eye Institute, 1945 CEI Drive, Cincinnati, OH, 45242, USADepartment of Ophthalmology at University of Cincinnati, 231 Albert Sabin Way, 5th Floor, Cincinnati, OH, 45267-0527, USA; Cincinnati Eye Institute, 1945 CEI Drive, Cincinnati, OH, 45242, USA; Corresponding author. Cincinnati Eye Institute 1945 CEI Drive, Cincinnati, OH, 45242, USA.Purpose: To present a case of aggressive proliferative vitreoretinopathy (PVR) managed with intraoperative and postoperative intravitreal methotrexate (MTX) in a patient with congenital aniridia (CI). Observations: A 41-year-old female with a history of CI, living-related conjunctival-kerato-limbal allograft transplantation, and multiple intraocular surgeries presents with tractional retinal detachment (TRD) and aggressive grade C PVR 52 days after a primary 23-gauge pars plana vitrectomy (PPV) with rhegmatogenous retinal detachment repair. She underwent 23-gauge PPV, TRD repair including membrane peeling of pre- and sub-retinal PVR, 5000 centistoke silicone oil exchange, endolaser, and MTX infusion. She received intravitreal 200 μg/0.05mL MTX every two weeks for a total of five injections before switching to monthly injections which have continued indefinitely. Five months after TRD repair, she had a small area of recurrent PVR inferiorly without associated retinal traction. She developed a small epithelial defect that resolved without complication. At 13 months, the patient remains at her visual acuity baseline of 20/125 and an attached retina without progression of PVR. Conclusions and importance: We report a favorable outcome in the management of aggressive PVR with intraoperative and postoperative intravitreal MTX in a patient with CI. Despite a history of limbal stem cell deficiency and receiving numerous MTX injections, keratopathy was minimal. Further research is required to study the safety and efficacy of MTX in the prophylaxis and treatment of aggressive fibrotic responses often seen in CI.http://www.sciencedirect.com/science/article/pii/S2451993624002263Proliferative vitreoretinopathyRetinal detachmentCongenital aniridiaMethotrexateAniridia fibrosis syndrome |
| spellingShingle | Naveen R. Ambati Christopher D. Riemann Intraocular use of methotrexate (MTX) for the treatment of proliferative vitreoretinopathy (PVR) in congenital aniridia (CI) and a possible link to aniridia fibrosis syndrome (AFS) treatment American Journal of Ophthalmology Case Reports Proliferative vitreoretinopathy Retinal detachment Congenital aniridia Methotrexate Aniridia fibrosis syndrome |
| title | Intraocular use of methotrexate (MTX) for the treatment of proliferative vitreoretinopathy (PVR) in congenital aniridia (CI) and a possible link to aniridia fibrosis syndrome (AFS) treatment |
| title_full | Intraocular use of methotrexate (MTX) for the treatment of proliferative vitreoretinopathy (PVR) in congenital aniridia (CI) and a possible link to aniridia fibrosis syndrome (AFS) treatment |
| title_fullStr | Intraocular use of methotrexate (MTX) for the treatment of proliferative vitreoretinopathy (PVR) in congenital aniridia (CI) and a possible link to aniridia fibrosis syndrome (AFS) treatment |
| title_full_unstemmed | Intraocular use of methotrexate (MTX) for the treatment of proliferative vitreoretinopathy (PVR) in congenital aniridia (CI) and a possible link to aniridia fibrosis syndrome (AFS) treatment |
| title_short | Intraocular use of methotrexate (MTX) for the treatment of proliferative vitreoretinopathy (PVR) in congenital aniridia (CI) and a possible link to aniridia fibrosis syndrome (AFS) treatment |
| title_sort | intraocular use of methotrexate mtx for the treatment of proliferative vitreoretinopathy pvr in congenital aniridia ci and a possible link to aniridia fibrosis syndrome afs treatment |
| topic | Proliferative vitreoretinopathy Retinal detachment Congenital aniridia Methotrexate Aniridia fibrosis syndrome |
| url | http://www.sciencedirect.com/science/article/pii/S2451993624002263 |
| work_keys_str_mv | AT naveenrambati intraocularuseofmethotrexatemtxforthetreatmentofproliferativevitreoretinopathypvrincongenitalaniridiaciandapossiblelinktoaniridiafibrosissyndromeafstreatment AT christopherdriemann intraocularuseofmethotrexatemtxforthetreatmentofproliferativevitreoretinopathypvrincongenitalaniridiaciandapossiblelinktoaniridiafibrosissyndromeafstreatment |